Tim Anderson
Tim Anderson
Timothy Devon Andersonis an American professional baseball shortstop for the Chicago White Sox of Major League Baseball. Anderson played college baseball at East Central Community College, and was selected in the first round of the 2013 MLB draft by the White Sox. He made his MLB debut on June 10, 2016...
ProfessionBaseball Player
Date of Birth23 June 1993
earnings growth guidance revenue seems tells
Merck tells an interesting story, yet the five-year revenue and earnings growth guidance seems far-fetched.
cancer data revenue translate
While the breast cancer data is interesting, we don't think it will translate into a significant new revenue stream.
biggest deals hurdle issues management run
The biggest hurdle in deals like these is the management issues - who will run the company.
action again based beat clearly credit deserves equity higher increased investors itself starting strong taking together
The beat was based on a combination of strong top-line growth, increased equity income, and higher other revenue. Merck deserves credit for starting to take action to put itself back together again and investors are clearly taking up the story.
burnt fortune good great hole knocking last putt
I had the good fortune of knocking my 2-3-foot putt in on the last hole and Doug's just burnt the edge. He was a great competitor.
bad good quarter quiet
It was a good quarter and quiet with no surprises, which is never a bad thing.
bounce statement team
We just had to bounce back strong. This was a statement our team had to make.
believes hope money private sector
The private sector believes they can make money at this, and we hope they do.
ahead company consensus expect good guidance negative
We expect the company to put up a good show, give guidance that is ahead of consensus and not have any significant negative surprises.
forward good looks moves moving
Anything that moves it forward is a good thing, and this looks like it's moving forward.
coming convert depends few generation next people quarters second shoes visibility
Schering will be coming out with a second generation (Claritin) drug in the next few months, so it depends how many people they convert (to the new drug), ... They could be in Merck's shoes a few quarters from now, but I don't think they have the visibility to say.
bad cheap news reason stocks
You've had nothing but bad news on the group, ... It's a reason why the stocks are cheap generally.
advantage area great hope schools start
This is great news. I really hope other schools in the area will take advantage of this and start participating.
areas brings deal good management shows
This is a pretty good deal for King. It brings them into new therapeutic areas and shows management is aggressive.